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Objectives: For patients with unresectable pancreatic cancer (PC), the efficacy and safety of molecular
targeted agents (MTAs) in combination with gemcitabine are still unclear. Published randomized con-
trolled trials (RCTs) have reported conflicting results. This study aimed to conduct a systematic review of
the literature and to perform a meta-analysis if appropriate.
Methods: Seven electronic databases were searched using a standard technique to November 2011
without restriction on publication status or language. The primary aim was to assess overall survival (OS).
Secondary aims were to assess progression-free survival (PFS), overall response rates (ORRs) and grade
3, 4 and 5 toxicities. A random-effects model was used for the meta-analysis.
Results: Seven Phase III RCTs were identified; 1981 patients were treated with MTAs and gemcitabine,
and 1992 patients received gemcitabine with or without placebo. No statistically significant difference in
OS was found between the two groups [hazard ratio (HR) = 0.93, 95% confidence interval (CI) 0.85–1.02;
P = 0.13]. The addition of MTAs improved PFS (HR = 0.86, 95% CI 0.79–0.93; P = 0.000) and ORR (odds
ratio 1.35, 95% CI 1.05–1.74; P = 0.01). However, these benefits were accompanied by significantly
higher toxicity (P = 0.001).
Conclusions: The findings of this study suggest that the palliation of PC with gemcitabine and MTAs
does not provide a significant survival benefit and is associated with increased grade 3 and 4 toxicities.
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Introduction
Pancreatic adenocarcinoma is a common gastrointestinal malig-
nancy. In the USA it is the fourth largest cause of cancer-
related mortality and accounts for approximately 42 500 new
cases and 35 000 deaths each year.1 Its prognosis is poor and
surgical resection is the only potential cure,2 but feasible in only
a minority of patients because of metastatic or locally advanced
disease.3–5 Palliative chemotherapy with gemcitabine offers better
overall survival (OS) and quality of life6 in comparison with
fluorouracil or best supportive care,7,8 but its benefits are
modest.
In recent years, the use of biological agents in combination with
standard chemotherapy has improved the outcomes of patients
with advanced colorectal cancer and other gastrointestinal
tumours.9 Consequently, several Phase III trials10–14 testing the role
of gemcitabine in combination with new biological agents have
been carried out in patients with unresectable pancreatic cancer
(PC). These studies have produced contradictory results with only
one trial10 showed a positive effect on OS. In view of this a sys-
tematic review of the literature was performed, with the appraisal
and analysis of all published Phase III randomized controlled
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trials (RCTs) that used molecular targeted agents (MTAs) in
addition to standard chemotherapy for patients with unresectable
PC.
Materials and methods
Data sources and study selection
PubMed, Excerpta Medical Database, Scopus, Web of Science, the
Cochrane Central Register of Controlled Trials, the hepatobiliary
group in the Cochrane Library, EMBASE and CINAHL were
searched for Phase III RCTs comparing standard palliative che-
motherapy with gemcitabine alone or in combination with
placebo vs. gemcitabine with the addition of MTAs. The search
applied to papers published to November 2011 without restriction
on publication status or language. To identify all potential papers,
medical subject headings reported in Table 1 were used with a
Boolean search strategy.15 Articles cited in the reference lists of all
potential studies were further reviewed and a comprehensive
database to catalogue the medical literature on this topic was
developed.
Two reviewers (KME and MM) independently assessed the eli-
gibility of all potential abstracts and titles. In cases of disagree-
ment or in the presence of insufficient information, the full text of
the study was reviewed for eligibility. The decision to include
articles in this study was reached by consensus. Principal investi-
gators of potential trials were asked for missing data and updates
by electronic mail whenever the study data were insufficiently
described. Phase I and II RCTs, non-controlled clinical trials,
studies on animals and review articles were excluded.
Definition of molecular target agents
Molecular targeted agents were defined as all the biological mol-
ecules able to alter at least one of the following neoplastic cellular
pathways: intracellular or intercellular signalling; metabolic
activities, and mytosis.16 The MTAs included for this study were
required to be approved for clinical trials on human subjects,
alone or in combination with other chemotherapy agents, for the
scope of improving tumour response, survival and symptoms in
patients affected by PC.
Outcomes
The primary outcome of this study was OS in patients receiving at
least one cycle of chemotherapy. Secondary outcomes were:
progression-free survival (PFS); overall response rate (ORR), and
incidences of grade 3, 4 and 5 toxicities according to the National
Cancer Institute Common Toxicity Criteria.17 Overall survival was
defined as the time interval between the date of enrolment in the
protocol and death. Progression-free survival was defined as the
time interval during which the size of the tumour remained stable
and ORR was defined as the sum of complete and partial tumour
Table 1 Summary of the terms used singly or in combination for evidence acquisition
Primary MeSH terms Secondary MeSH terms Keywords
Pancreas Antineoplastic protocol(s) Gemcitabine
Pancreatic duct(s) Drug therapy, combination Pemetrexed
Pancreatic disease(s) Antineoplastic combined chemotherapy protocols Marimastat
Pancreatic neoplasm(s) Randomized controlled trial Tipifarnib
Adenocarcinoma(s) Clinical trials, Phase III Bevacizumab
Neoplasm metastasis Controlled clinical trial(s) Cetuximab
Palliative care Double-blind method Erlotinib
Drug therapy Research design Axitinib
Treatment outcome Epidemiologic research design
Outcome assessment Adult
Clinical trial(s) Deoxycitidine
Random allocation Early termination of clinical trials
Humans Treatment failure
Cytidine Angiogenesis inhibitor(s)
Deoxyribonucleosides Antimetabolite(s)
Antineoplastic agent(s) Anticarcinogenic agent(s)
Molecular targeted therapy Receptor protein-tyrosine kinase(s)
Antibodies, monoclonal Receptor, epidermal growth factor
Angiogenesis modulating agent(s) Angiogenesis inhibitor(s)
Growth inhibitor(s) Receptor, vascular endothelial growth factor
Metalloendopeptidases Platelet-derived growth factor
Folic acid antagonists
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responses by RECIST (response evaluation criteria in solid
tumours) criteria,18 divided by the number of included patients.
Data extraction
Two reviewers (KME and MM) independently extracted the data
of interest in each study. The following variables were collected:
the name of the primary author; year of publication; country in
which the study was performed; number of patients randomized
in each arm; dosage of anti-cancer therapy; allocation sequence
generation; allocation concealment; power calculation; study
design; methods used to deal with missing data, and appropriate
description of attrition and drop-outs. For each study, the follow-
ing clinical variables of interest were extracted: OS; PFS; ORR, and
grade 3, 4 and 5 drug-induced toxicities.
Assessment of study quality
The Cochrane Collaboration risk assessment tool was used to
score the quality of the studies.19 The randomization methods
were classified as the primary means to control bias and the ran-
domization process was evaluated by the methods used to gener-
ate and conceal the allocation sequence. Adequate randomization
methods were based on a table of random numbers, computer-
generated allocation or equivalent techniques. Allocation conceal-
ment was considered adequate if it was obtained by a central
randomization system, if coded drugs that appeared identical
were used, if serially numbered opaque sealed envelopes were
employed or if other equivalent methods were used. Blinding was
extracted and appraised for caregivers, patients and assessors.
Risk for attrition bias was assessed by the number of and reason
for drop-outs and withdrawals and whether all patients were
accounted for and analysed. The quality of studies was assessed
according to sample size calculations and whether or not the
sample size had been achieved, whether the study included clear
definitions of primary outcomes, and whether or not a crossover
design had been used.
Statistical analysis
Statistical analysis was performed using Comprehensive Meta-
Analysis Version 2 software.20 Meta-analysis was performed using
a random-effects model21 in response to the expected clinical het-
erogeneity among the trials. The results were reported as hazard
ratios (HRs) with 95% confidence intervals (CIs) for OS and PFS
analyses. Pooled odds ratios (ORs) with 95% CIs were applicable
for response rates and drug toxicities. For the primary outcome,
sensitivity analysis was performed to assess the impact of studies
with higher risk for bias. The main modality for presenting
numerical data in visual form was the forest plot.
Reporting
The PRISMA Statement was used for reporting the strategy used
to identify Phase III RCTs, inclusion and exclusion criteria, assess-
ment of bias and the results of this meta-analysis.22
Results
Ascertainment of the studies
The search strategy used to identify Phase III trials on the topic of
interest detected a total of 163 publications. Initial screening
reduced this number to a total of 61 potentially relevant trials.
Reading of the content of abstracts and appraisals of eligibility
further reduced this number to seven Phase III RCTs that satisfied
the inclusion criteria of the present study (Fig. 1).
Study characteristics
Table 2 summarizes the characteristics of all included studies. All
trials were multicentric; the total number of patients per study
ranged from 239 to 745, giving a combined total of 3973 partici-
pants. Each of the RCTs that satisfied the inclusion criteria
involved an experimental arm in which patients received gemcit-
abine chemotherapy combined with one of the following MTAs:
bevacizumab; cetuximab; erlotinib; marimastat; axitinib; pemetr-
exed, and tipifarnib. In five trials10,11,13,14,23 the control groups
received gemcitabine and placebo, and in two trials12,24 the control
groups received gemcitabine only.
In total, 1981 patients received gemcitabine and MTAs, and
1992 subjects underwent conventional chemotherapy with a
single cytotoxic agent.
Risk for bias
The allocation system was described in all seven trials; however,
none reported enough details on the strategy used for allocation
concealment. The majority of the trials were blinded to both
patients and observers. Methods of handling missing data were
not adequately described in any of the included studies
(Table 3).
All the RCTs had similar designs and compared the effects of
gemcitabine vs. gemcitabine in combination with a single MTA
for palliation of unresectable PC without the addition of radiation
therapy. Consequently, both authors agreed to perform a meta-
analysis for the primary and secondary outcomes.
Primary outcome
Overall survival
Although the overall trend favoured the use of MTAs, the pooled
analysis did not demonstrate any significant difference between
the two groups (HR = 0.94, 95% CI 0.87–1.01; P = 0.09) (Fig. 2).
A sensitivity analysis was performed by excluding the 2010 study
by Kindler et al.14 as it was the only trial to show a relatively better
survival benefit in the placebo group and was therefore considered
as an outlier. The meta-analysis of the six remaining studies con-
firmed no difference in OS between the two arms.
Secondary outcomes
The pooled analysis for PFS showed a statistically significant
improvement in the study arm treated with MTAs (HR = 0.86,
95% CI 0.79–0.93; P = 0.000) (Fig. 3). Similarly, the ORR differed
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the two therapeutic arms, favouring the use of MTAs (OR = 1.35,
95% CI 1.05–1.74; P = 0.01) (Fig. 4). By contrast, effects of grade
3 and 4 toxicities (e.g. anaemia, neutropenia, thrombocytopenia,
cerebrovascular accidents, proteinuria, venous thrombosis, skin
rash, nausea/vomiting, anorexia) were more common in the
group treated with MTAs (OR = 1.79, 95% CI 1.50–2.13; P = 0.00)
(Fig. 5). A higher risk for treatment-related mortalities (grade 5
toxicities) was also seen in patients receiving a combination of
gemcitabine and MTAs in all studies except one11 (pooled
OR = 2.19, 95% CI 1.19–4.0; P = 0.01) (Fig. 6).
Sensitivity analysis and publication bias
Sensitivity analysis did not show any difference in results for either
primary or secondary outcomes. Assessment for publication bias
performed using a funnel plot of the standard errors suggested
that the risk for publication bias was minimal as a result of the
symmetrical distribution of the relationship between treatment
effect and study size25 (Fig. 7).
Discussion
Since 1997, gemcitabine-based chemotherapy has become the ref-
erence treatment for patients with unresectable PC.7 During the
subsequent years, many combinations of chemotherapy regimens
have been tried for unresectable PC without considerable benefits.
Only one Phase III trial showed a synergistic effect of gemcitabine
and erlotinib, with a median survival of 6.24 months compared
with 5.91 months in the gemcitabine-only arm.10
Among many negative chemotherapy trials, a recent European
multicentre study shown a significant improvement in OS in
patients treated with the combination of oxaliplatin, irinotecan,
leucovorin and fluorouracil (FOLFIRINOX) in comparison with
gemcitabine alone.26 This trial generated some optimism for che-
motherapy protocols that combine several agents to minimize
side-effects and take advantage of the synergistic effects of com-
pounds that act at different cellular levels.
This trial fits well with the recent identification of several
molecular abnormalities occurring in solid tumours, and the
development of new chemotherapy agents designed to act on
specific cellular targets.27
Data from laboratory research have shown that MTAs are able
to alter the expected course of neoplastic cells28,29 with precision
and without altering the cycle of normal cells.30 For some
solid and haematological tumours, these effects have been proven
in clinical trials, with significant extension of OS and, in some
cases, complete response.30 The success of MTAs for the treatment
of some other gastrointestinal tumours9 has generated the
hypothesis that MTAs might also be beneficial in PC.30 Similarly to
other solid tumours, the development of PC involves multiple
genetic and epigenetic alterations, chromosomal aberrations, gene
mutations and several changes of molecular pathways31 that may
be amenable to pharmacologic interference by MTAs.
Because PC cells are resistant to conventional chemotherapy
agents, and there is no single very effective cytotoxic agent, several
Phase III RCTs have been carried out to investigate the effects of
MTAs in combination with gemcitabine. All these trials were very
163 potential articles identified through database searching
61 articles were screened for inclusion by appraising
the content  of their abstracts
102 articles removed by reviewing the title of the study
42 articles were removed:
• 23 non-randomized controlled trials
• 19 other interventions
7 articles included in quantitative analysis
54 articles were removed:
• 27 studies compared cytotoxic agents
• 5 studies analysed quality of life only
• 1 study included radiation therapy
• 1 study focused on serum changes of molecular tumour markers
• 20 studies did not satisfy the inclusion criteria for several other 
reasons such as they were non-randomized or compared 
several combinations of treatments
Figure 1 Flow of information through the different phases of the systematic review
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well designed, adequately powered and reported proper follow-up
and survival. However, despite optimistic expectations, only one
study10 was able to show a positive statistical difference in OS
between the treatment arms.
Single experiments very rarely provide definitive answers to
research questions; therefore a systematic review of the literature
was performed. After an extensive search of several databases, all
the potential Phase III RCTs that satisfied the inclusion criteria
were selected. The available studies had very similar designs and
objectives, and agreement was reached that the criteria for a
quantitative synthesis were satisfied and a meta-analysis was sub-
sequently performed.
The results of this study confirmed that the addition of an MTA
did not translate into significant OS benefits, although PFS and
ORR were statistically better than in the control arms. By contrast,
the addition of MTAs resulted in a significant increase of grade 3
and 4 and, more importantly, grade 5 toxicities.
One of the limitations of this study was the fact that the MTAs
tested in the trials were heterogeneous in terms of their molecular
structure and specific targets. Some MTAs were selective inhibi-
Table 2 Characteristics of the included trials
Authors (year) Country
(randomized patients, n)
Intervention arm 1 Patients
analysed, n
Intervention arm 2 Patients
analysed, n
Outcomes Outcomes
Bramhall et al. (2002)11 USA, UK (239) Gemcitabine + marimastat 120a, 118b Gemcitabine + placebo 119a, 117b
Median OS: 165.5 days Median OS: 164 days
PFS: 92.5 days PFS: 96 days
Overall RR: 11% Overall RR: 16%
Grade 5 toxicity: 0% Grade 5 toxicity: 0%
van Cutsem et al. (2004)13 International (688) Gemcitabine + tipifarnib 341a, 331b Gemcitabine + placebo 347a, 342b
Median OS: 193 days Median OS: 182 days
PFS: 112 days PFS: 109 days
Overall RR: 6% Overall RR: 8%
Grade 5 toxicity: 3% Grade 5 toxicity: 2%
Oettle et al. (2005)24 International (565) Gemcitabine + pemetrexed 283a, 273b Gemcitabine 282a, 273b
Median OS: 6.2 months Median OS: 6.3 months
PFS: 3.9 months PFS: 3.3 months
Overall RR: 14.8% Overall RR: 7.1%
Grade 5 toxicity: 1.4% Grade 5 toxicity: 0%
Moore et al. (2007)10 International (569) Gemcitabine + erlotinib 285a, 282b Gemcitabine + placebo 284a, 280b
Median OS: 6.24 months Median OS: 5.91 months
PFS: 3.75 months PFS: 3.55 months
Overall RR: 8.6% Overall RR: 8.0%
Grade 5 toxicity: 2.1% Grade 5 toxicity: 0%
Philip et al. (2010)12 USA, Canada (745) Gemcitabine + cetuximab 372a, 361b Gemcitabine 371a, 355b
Median OS: 6.3 months Median OS: 5.9 months
PFS: 3.4 months PFS: 3.0 months
Overall RR: 12% Overall RR: 14%
Grade 5 toxicity: 1.9% Grade 5 toxicity: 0.2%
Kindler et al. (2010)14 USA (602) Gemcitabine + bevacizumab 302a, 277b Gemcitabine + placebo 300a, 263b
Median OS: 5.8 months Median OS: 5.9 months
PFS: 3.8 months PFS: 2.9 months
Overall RR: 13% Overall RR: 10%
Grade 5 toxicity: 3.6% Grade 5 toxicity: 1.1%
Kindler et al. (2011)23 International (632) Gemcitabine + axitinib 314a, 305b Gemcitabine + placebo 316a, 308b
Median OS: 8.5 months Median OS: 8.3 months
PFS: 4.4 months PFS: 4.4 months
Overall RR: 5% Overall RR: 2%
Grade 5 toxicity: 1.6% Grade 5 toxicity: 0.6%
Total patients randomized: n = 4040 Patients analysed for
efficacy: n = 2017
Patients analysed for
safety: n = 1947
Patients analysed for
efficacy: n = 2019
Patients analysed for
safety: n = 1938
aNumber of patients analysed for efficacy.
bNumber of patients analysed for safety.
OS, overall survival; PFS, progression-free survival; RR, response rate.
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tors of trans-membrane receptors and others were inhibitors of
intracellular enzymes responsible for cellular replication, angio-
genesis and promotion of metastases. However, although each
MTA acted on a unique target, their final effects could be unified
as one of the following: inhibition of angiogenesis and cell growth,
or prevention of the degradation of basement membranes and
migration of endothelial cells needed to form blood vessels. All the
trials were based on the concept that MTAs are complementary
drugs to the main cytotoxic agent gemcitabine and tested the
hypothesis that MTAs might be synergistic.
Another limitation was the relatively small number of trials,
although the total number of patients included in the meta-
Table 3 Risk for bias in the published controlled trials
Authors (year) Allocation
system
described
Allocation
concealment
Blinding:
patient
Blinding:
personnel
Blinding:
assessor
Handling of
missing data
Power calculation
for number of
patients to
be treated
Kindler et al. (2010)14 Yes NA Yes Yes NA Unclear Yes
Philip et al. (2010)12 Yes NA NA NA NA Unclear Yes
Moore et al. (2007)10 Yes NA Yes Yes NA Unclear Yes
Bramhall et al. (2002)11 Yes NA Yes Yes NA Unclear Yes
van Cutsem et al. (2004)13 Yes NA Yes Yes NA Unclear Yes
Kindler et al. (2011)23 Yes Yes Yes Yes NA Unclear Yes
Oettle et al. (2005)24 Yes NA Yes NA NA Unclear Yes
NA, not available.
Study name Statistics for each study Hazard ratio and 95% CI
0.5 1 2
Gem + MTA
Hazard
ratio
Lower
limit
Upper
limit Z-value P-value
Gem + placebo
Bramhall et al.(2002) 0.990 0.757 1.295 0.941–0.073
Kindler et al.(2010) 0.957 0.806 1.136 0.616–0.502
Kindler et al.(2011) 0.986 0.764 1.273 0.914–0.108
Oettle et al.(2005) 0.980 0.817 1.176 0.828–0.218
0.941 0.877 1.010 0.094–1.675
0.820 0.685 0.982 0.031–2.155Moore et al.(2007)
0.943 0.811 1.096 0.444–0.766Philip et al.(2010)
0.971 0.812 1.161 0.745–0.325van Cutsem et al.(2004)
Figure 2 Forest plot representing the pooled results for overall survival in patients treated with gemcitabine (Gem) and molecular targeted
agents (MTAs) vs. Gem alone or in combination with placebo. 95% CI, 95% confidence interval
Study name Statistics for each study Hazard ratio and 95% CI
0.5 1 2
Hazard
ratio
Lower
limit
Upper
limit Z-value P-value
Gem + MTA Gem + placebo
Moore et al.(2007) 0.770 0.642 0.923 –2.823 0.005
van Cutsem et al.(2009) 0.730 0.615 0.867 –3.592 0.000
0.862 0.797 0.933 –3.683 0.000
Philip et al.(2010) 0.930 0.804 1.076 –0.978 0.328
Kindler et al.(2011) 0.970 0.819 1.149 –0.353 0.724
Bramhall et al.(2002) 0.950 0.732 1.233 –0.385 0.700
Figure 3 Forest plot representing the pooled results for progression-free survival in patients treated with gemcitabine (Gem) and molecular
targeted agents (MTAs) vs. Gem alone or in combination with placebo. Progression-free survival was reported in median months by Oettle
et al.24 and by Kindler et al.14 and therefore these were not included in the meta-analysis for this outcome. 95% CI, 95% confidence interval
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Study name Statistics for each study Odds ratio and 95% CI
0.5 1 2
Gem + MTAGem + placebo
Bramhall et al.(2002) 0.757 0.329 1.743 0.531–0.655
Kindler et al.(2010) 1.335 0.805 2.212 0.2631.119
Philip et al.(2010) 1.246 0.702 2.212 0.4530.750
van Cutsem et al.(2004) 0.759 0.261 2.211 0.613–0.506
1.356 1.054 1.744 0.0182.372
3.204 1.01910.074 0.0461.992Kindler et al.(2011)
1.095 0.599 2.002 0.7680.295Moore et al.(2007)
2.295 1.292 4.076 0.0052.835Oettle et al.(2005)
Odds
ratio
Lower
limit
Upper
limit Z-value P-value
Figure 4 Forest plot representing the pooled results for objective response rate in patients treated with gemcitabine (Gem) and molecular
targeted agents (MTAs) vs. Gem alone or in combination with placebo. 95% CI, 95% confidence interval
Study name Statistics for each study Odds ratio and 95% CI
0.5 1 2
Gem + MTAGem + placebo
Odds
ratio
Lower
limit
Upper
limit Z-value P-value
Bramhall et al.(2002) 0.889 0.535 1.477 0.650–0.454
Kindler et al.(2010) 1.559 0.913 2.661 0.1041.627
Kindler et al.(2011) 1.667 1.190 2.335 0.0032.971
Oettle et al.(2005) 5.236 3.619 7.575 0.0008.787
1.793 1.508 2.132 0.0006.611
1.107 0.739 1.659 0.6210.494Moore et al.(2007)
1.479 0.677 3.232 0.3260.982Philip et al.(2010)
1.259 0.629 2.520 0.5160.650van Cutsem et al.(2004)
Figure 5 Forest plot representing the pooled results for grade 3 and 4 toxicities in patients treated with gemcitabine (Gem) and molecular
targeted agents (MTAs) vs. Gem alone or in combination with placebo. 95% CI, 95% confidence interval
Study name Statistics for each study Odds ratio and 95% CI
0.01 0.1 1 10 100
Gem + MTAGem + placebo
Odds
ratio
Lower
limit
Upper
limit Z-value P-value
Kindler et al.(2010) 3.390 0.924 12.444 0.0661.840
Kindler et al.(2011) 1.010 0.289 3.525 0.9880.016
Oettle et al.(2005) 9.134 0.489 170.466 0.1391.481
2.192 1.198 4.009 0.0112.546
13.233 0.742 236.005 0.0791.757Moore et al.(2007)
7.020 0.859 57.349 0.0691.818Philip et al.(2010)
1.482 0.557 3.940 0.4310.788van Cutsem et al.(2004)
Figure 6 Forest plot representing the pooled results for grade 5 toxicities (treatment-related deaths) in patients treated with gemcitabine
(Gem) and molecular targeted agents (MTAs) vs. Gem alone or in combination with placebo. Bramhall et al.11 reported no grade 5 toxicities
in either treatment arm. 95% CI, 95% confidence interval
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analysis was conspicuous. In fact, the final number of subjects
pooled in this meta-analysis was sufficient to power an RCT able
to detect a minimum difference in HR of 0.1.
Along with these limitations, this study has several strengths.
The first of these was the high quality and the homogeneity of the
design and interventions of all the included studies and the fact
that an extensive literature search was performed to establish the
most up-to-date information on the effects of novel MTAs in PC.
Secondly, a relatively large number of patients (3973) was
included, and two reviewers were involved in assessing potential
bias and in extracting data in a manner that has been shown to
improve the quality of meta-analysis. As a final point, this study
assessed not only potential survival benefits, but also other impor-
tant clinical outcomes such as response rates, grade 3 and 4 tox-
icities, and treatment-related mortality.
This is the first meta-analysis on the results of MTAs in the
treatment of unresectable PC. For reasons that are still not very well
understood, PC appears to be very resistant, not only to well-
known cytotoxic agents, but also to the MTAs currently available.
The findings of this study do not support the use of available
MTAs in combination with gemcitabine for the palliation of
patients affected by advanced PC. Although the enthusiasm for
MTAs in PC has declined because of their modest effects and high
costs, further RCTs combining MTAs with FOLFIRNOX should be
encouraged. In further trials, cost-effective analyses should also be
included among the outcomes of interest as the costs of adding
MTAs to other cytotoxic agents will remain a significant constraint
on the wide use of these agents in the treatment of patients with PC.
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